Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN EBITDA Margin

EBITDA as a percentage of revenue.

Agenus Inc.NASDAQ: AGEN

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 161.5%

EBITDA Margin was 161.5% in Q1 FY2026, up 204.6 pp from a year earlier. On a trailing-twelve-month basis it was 102.6%, up 184.0 pp year over year. Over 3 fiscal years it widened by 219.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 97.2% for the fiscal year ending Dec 2026, up from 54.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
161.5%+143.9 pp QoQ
Last fiscal yearDec 2025
54.5%+152.4 pp YoY
LTMMar 2026
102.6%+184.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+204.6 pp+113.9 pp-90.7 pp
1 year+152.4 pp+42.7 pp-109.6 pp
3 years+219.6 pp+16.1 pp-203.5 pp
5 years+9.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
54.5%
Year-over-year change
+152.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 EBITDA Margin of 102.6% is the highest of the 5 companies compared; the peer median is -1366.5%.
  • Its year-over-year change of +184.0 pp is the highest of 5, against a peer median of -674.2 pp.
  • Over three fiscal years its change of +219.6 pp compares with a peer median of -1008.7 pp.
AGEN Competitors Peer median
EBITDA Margin for AGEN and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 2026102.6% +184.0 pp+219.6 pp
SEERSeer, Inc.LTM Mar 2026-427.9% +95.5 pp+175.4 pp
IRDOpus Genetics, Inc.LTM Mar 2026-874.0% -638.6 pp-384.3 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-1859.1% -709.8 pp-1633.0 pp
INOInovio Pharmaceuticals, Inc.FY2025-125425.9% -77690.7 pp-122786.1 pp
TTRXTurn Therapeutics Inc.FY2025— ——
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
HURATuHURA Biosciences, Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding AGEN) -1366.5%-674.2 pp-1008.7 pp

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.67M98.02M156.31M103.46M114.2M
Cost of Revenue182.08M197.26M237.68M156.01M80.36M
Gross Profit113.59M(99.24M)(81.37M)(52.55M)33.84M
Gross Margin38.4%-101.2%-52.1%-50.8%29.6%
Research & Development178.61M0234.57M155.53M0
Selling, General & Admin76.36M81.01M78.74M71.88M54.39M
Operating Expenses87.84M80.19M78.18M67.92M54.39M
Depreciation & Amortization6.79M6.95M13.59M13.34M10M
EBITDA43.78M(161.85M)(145.92M)(101.3M)62.19M
EBITDA Margin14.8%-165.1%-93.4%-97.9%54.5%
Operating Income25.75M(179.43M)(159.55M)(120.48M)(20.56M)
Operating Margin8.7%-183.0%-102.1%-116.4%-18.0%
Interest Income00000
Interest Expense65.72M61.86M97.93M117.63M55.27M
Other Income / Expenses(54.47M)(51.23M)(97.89M)(111.8M)17.47M
Income Before Tax(28.72M)(230.66M)(257.44M)(232.27M)(3.08M)
Pre-Tax Margin-9.7%-235.3%-164.7%-224.5%-2.7%
Income Tax Expense00000
Net Income(23.93M)(220.07M)(245.76M)(227.21M)115K
Net Margin-8.1%-224.5%-157.2%-219.6%0.1%
EPS (Basic)(2.11)(15.64)(13.75)(10.59)(0.00)
EPS (Diluted)(2.11)(15.64)(13.75)(10.59)(0.00)
Weighted Avg Shares11.45M14.09M17.89M21.47M29.73M
Weighted Avg Shares (Diluted)11.45M14.09M17.89M21.47M29.73M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.